BHC - Bausch Health Acquisition Of Synergy Assets Should Increase Valuation By $1 Billion
It was an extremely sad day for Synergy Pharmaceuticals (SGYP) shareholders last week as a scheduled auction for February 26 didn't go through as no other bidders submitted offers to buy the company assets or proposed a plan of reorganization.
Synergy whose market cap at one time surpassed the $1.2 billion market cap mark has sold its possible blockbuster drug Trulance and possibly colorectal cancer prevention drug Dolcanatide for proceeds of approximately $195 million.
Data by YChartsSince the week of June 12, 2017, scripts of Trulance had been growing on average 2.43%